Tempest Therapeutics (TPST) news
Recent news
Tempest appoints John W. Frederick to board of directors, strengthening financial and capital markets expertise
Tempest Therapeutics, Inc. (NASDAQ: TPST) has appointed John W. Frederick to its board of directors, enhancing the company’s financial and capital markets expertise. Frederick brings successful business initiatives , according to company disclosures. His appointment follows a series of significant…
AInvest Wire · 19h agoTempest Therapeutics Inc: H.C. Wainwright cuts target price to $7 from $11
H.C. Wainwright & Co. has revised its price target for Tempest Therapeutics Inc (NASDAQ: TSTM), lowering it from $11 to $7, effective September 24, 2026[1]. The adjustment reflects the firm’s reassessment of the company’s near-term clinical and regulatory outlook. Despite the reduced target, the…
AInvest Wire · Sep 24, 2026Tempest Therapeutics Inc: Entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd
Tempest Therapeutics Inc. (Nasdaq: TPST) has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd., granting Senlang the right to negotiate and potentially enter into definitive license agreement for TPST-4003 in China. This agreement is part of a broader…
AInvest Wire · Sep 15, 2026Tempest Therapeutics - No grade 3 or higher cytokine release syndrome or neurotoxicity as of Aug 25, 2026
Tempest Therapeutics has reported that as of August 25, 2026, no instances of grade 3 or higher cytokine release syndrome or neurotoxicity were observed in its ongoing clinical trials. This update comes amid continued monitoring of safety and efficacy profiles for its investigational therapies. The…
AInvest Wire · Sep 15, 2026Tempest secures exclusive option to license clinical-stage CD7-targeted lentiviral in vivo CAR-T platform
Tempest Therapeutics, Inc. (Nasdaq: TPST) has entered into a strategic collaboration with Hebei Senlang Biotechnology Co., Ltd., granting Senlang an exclusive option to negotiate and enter into a definitive license agreement for Tempest’s TPST-4003 in China. This partnership aims to advance…
AInvest Wire · Sep 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.